Backward

Resveratrol:Trans-3,5,4'-trihydroxystilbene.:Introduction and Its Benefit Applications.

article content dotArticle Content:

product dotProducts Related:Resveratrol:Trans-3,5,4'-trihydroxystilbene.

Resveratrol:Trans-3,5,4'-trihydroxystilbene CAS:501-36-0 trans.61434-67-1.cis transresveratrol flavonoids,Phytoestrogen,Antioxidant,Anticancer,Antitoxic photo picture image arrowitembigName:Resveratrol:Trans-3,5,4'-trihydroxystilbene.
 Serie No:Pure03.
 Specifications:99%HPLC
 INCI Name:
 EINECS/ELINCS No.:
 CAS:501-36-0.(trans-).61434-67-1.(cis-)
 Chem/IUPAC Name: Trans-3,5,4'-trihydroxystilbene
 Click right photo or button for introduction details of Resveratrol:Trans-3,5,4'-trihydroxystilbene.Click for Details

applications dotApplications and Properties:

dotarrowrbApplications:

Phytoestrogen.
Antioxidant.
Anticancer.
Diabetes.
Heart health.
Increase of lifespan.
Antitoxic.
Anti-SARS.

dotarrowrgProperties:

Resveratrol is an antioxidant but its antioxidant properties are weaker that those of quercetin and epicatechin. It has anticancer properties and inhibits lipid peroxidation of low-density lipoprotein and prevents the cytotoxicity of oxidized LDL. Resveratrol also increases the activity of some antiretroviral drugs in vitro. Resveratrol is the parent compound of a family of molecules, including glucosides and polymers, existing in cis and trans configurations in a narrow range of spermatophytes of which vines, peanuts and pines are the prime representatives.
Dosages: recommended dosage of 5~10 mg(22~44 umol) per day.

dotarrowsg1Safety and Toxicity:

Human Studies:Adverse effects of resveratrol have not been reported:a recommended dosage of 5~10 mg(22~44 umol) per day was stated to be "entirely safe."Recently,the National Cancer Institute(NCI) initiated preclinical toxicity studies on trans-resveratrol: clinical trials may also be conducted.
Click for Details

Reference:

citations1.Resveratrol:Trans-3,5,4'-trihydroxystilbene.:Introduction and Its Benefit Applications.

last edit date:10th,Nov.2009.